Plasminogen activators and ischemic stroke: Conditions for acute delivery

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 4, 2013, Pages 406-425

  Del Zoppo, Gregory J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

acute intervention; hemorrhage; intra arterial; intravenous; plasminogen activators; stroke; thrombolysis; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; APIXABAN; CLOPIDOGREL; DABIGATRAN; DIPYRIDAMOLE; DUTEPLASE; FIBRINOGEN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLASMINOGEN ACTIVATOR; RECOMBINANT PLASMINOGEN ACTIVATOR; TICLOPIDINE; WARFARIN;

ANTICOAGULATION; ARTERY REOCCLUSION; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG HALF LIFE; FIBRINOLYTIC THERAPY; HUMAN; META ANALYSIS (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAGITTAL SINUS THROMBOSIS; SECONDARY PREVENTION; SYSTEMIC THERAPY; TRANSIENT ISCHEMIC ATTACK;

CEREBRAL HEMORRHAGE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84878273624     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1338126     Document Type: Article

References (267)

1. Mohr J. P., Caplan L. R., Melski J. W., et al. The Harvard Cooperative Stroke Registry: a prospective registry of patients hospitalized with stroke. Neurology: 1978; 28 8 754 762 (Pubitemid 8382975)
2. Mohr J. P., Barnett H. JM. Classification of ischemic strokes. In: Barnett H. JM, Stein B. M., Mohr J. P., Yatsu F. M., eds. Stroke: Pathophysiology, Diagnosis and Management, Vol. 1. New York Churchill Livingstone: 1986; 281 291
3. Solis O. J., Roberson G. R., Taveras J. M., Mohr J., Pessin M. S. Cerebral angiography in acute cerebral infarction. Rev Interam Radiol: 1977; 2 1 19 25
4. Fieschi C., Argentino C., Lenzi G. L., Sacchetti M. L., Toni D., Bozzao L. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci: 1989; 91 3 311 321
5. The National Institutes of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med: 1995; 333 1581 1587
6. del Zoppo G. J., Higashida R. T., Furlan A. J., Pessin M. S., Rowley H. A., Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke: 1998; 29 4 11 (Pubitemid 28046933)
7. Irino T., Taneda M., Minami T. Angiographic manifestations in postrecanalized cerebral infarction. Neurology: 1977; 27 5 471 475 (Pubitemid 8125725)
8. del Zoppo G. J., Poeck K., Pessin M. S., et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol: 1992; 32 1 78 86
9. Fieschi C., Bozzao L. Transient embolic occlusion of the middle cerebral and internal carotid arteries in cerebral apoplexy. J Neurol Neurosurg Psychiatry: 1969; 32 3 236 240
10. DeWood M. A., Spores J., Notske R., et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med: 1980; 303 16 897 902 (Pubitemid 10021186)
11. Kligman A. M. Long-term anticoagulant therapy after myocardial infarction. A study of 747 patients in 15 hospitals. JAMA: 1965; 193 929 934
12. Harvald B., Hilden T., Lund E. Long-term anticoagulant therapy after myocardial infarction. Lancet: 1962; 2 7257 626 630
13. Loeliger E. A., Hensen A., Kroes F., et al. A double-blind trial of long-term anticoagulant treatment after myocardial infarction. Acta Med Scand: 1967; 182 5 549 566
14. Breddin K., Loew D., Lechner K., Oberla K., Walter E. The German-Austrian Aspirin Trial: a comparison of acetylsalicyclic acid, placebo, and phenprocoumon in secondary prevention of myocardial infarction. Circulation: 1980; 62 (Suppl): V63 V72
15. Report of the Sixty Plus Reinfarction Study Research Group A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet: 1980; 2 8202 989 994
16. Smith P., Arnesen H., Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med: 1990; 323 3 147 152 (Pubitemid 20219942)
17. Sage J. I., Van Uitert R. L. Risk of recurrent stroke in patients with atrial fibrillation and non-valvular heart disease. Stroke: 1983; 14 4 537 540 (Pubitemid 13036778)
18. Hart R. G., Coull B. M., Hart D. Early recurrent embolism associated with nonvalvular atrial fibrillation: a retrospective study. Stroke: 1983; 14 5 688 693 (Pubitemid 13012338)
19. del Zoppo G. J. Prevention and treatment of acute stroke. In: Colman R. W., Marder V. J., Clowes A. W., George J. N., Goldhaber S. Z., eds. Hemostasis and Thrombosis. 5th ed. Philadelphia Lippincott, Williams & Wilkins: 2006; 1477 1496
20. Mundall J., Quintero P., Von Kaulla K. N., Harmon R., Austin J. Transient monocular blindness and increased platelet aggregability treated with aspirin. A case report. Neurology: 1972; 22 3 280 285
21. Harrison M. JG, Marshall J., Meadows J. C., Russell R. W. Effect of aspirin in amaurosis fugax. Lancet: 1971; 2 7727 743 744
22. Dyken M. L., Kolar O. J., Jones F. H. Differences in the occurrence of carotid transient ischemic attacks associated with antiplatelet aggregation therapy. Stroke: 1973; 4 5 732 736
23. Marshall J. The natural history of transient ischemic cerebrovascular attacks. Q J Med: 1964; 33 309 324
24. Wolf P. A., Kannel W. B., McGee D. L., Meeks S. L., Bharucha N. E., McNamara P. M. Duration of atrial fibrillation and imminence of stroke: the Framingham study. Stroke: 1983; 14 5 664 667 (Pubitemid 13012334)
25. Whisnant J. P., Matsumoto N., Elveback L. R. Transient cerebral ischemic attacks in a community. Rochester, Minnesota, 1955 through 1969. Mayo Clin Proc: 1973; 48 3 194 198
26. Caplan L. R. Are terms such as completed stroke or RIND of continued usefulness? Stroke: 1983; 14 3 431 433 (Pubitemid 13100327)
27. Johnston S. C., Rothwell P. M., Nguyen-Huynh M. N., et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet: 2007; 369 9558 283 292 (Pubitemid 46136488)
28. UK-TIA Study Group United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. Br Med J (Clin Res Ed): 1988; 296 6618 316 320
29. Denny-Brown D. Recurrent cerebrovascular episodes. Arch Neurol: 1960; 2 194 210
30. Russell R. WR. Atheromatous retinal embolism. Lancet: 1963; 2 7322 1354 1356
31. Hollenhorst R. W. Vascular status of patients who have cholesterol emboli in the retina. Am J Ophthalmol: 1966; 61 5 Pt 2 1159 1165
32. Barnett H. J. The pathophysiology of transient cerebral ischemic attacks. Med Clin North Am: 1979; 63 4 649 679
33. Marshall J. The Management of Cerebrovascular Diseases. Oxford, England Blackwell Scientific Publications: 1976
34. Dougherty J. H., Levy D. E., Weksler B. B. Platelet activation in acute cerebral ischemia. Lancet: 1977; 3 821 824
35. Mettinger K. L., Nyman D., Kjellin K-G, Sedén Å, Söderström C. E. Factor VIII related antigen, anti-thrombin III, spontaneous platelet aggregation and plasminogen activator in ischemic cerebrovascular disease. J Neurol Sci: 1979; 41 31 38 (Pubitemid 9083269)
36. de Boer A. C., Turpie A. G., Butt R. W., Duke R. J., Bloch R. F., Genton E. Plasma betathromboglobulin and serum fragment E in acute partial stroke. Br J Haematol: 1982; 50 2 327 334 (Pubitemid 12165675)
37. Cella G., Zahavi J., de Haas H. A., Kakkar V. V. beta-Thromboglobulin, platelet production time and pletelet function in vascular disease. Br J Haematol: 1979; 43 1 127 136 (Pubitemid 9251455)
38. Feinberg W. M., Bruck D. C., Ring M. E., Corrigan J. J. Jr. Hemostatic markers in acute stroke. Stroke: 1989; 20 5 592 597 (Pubitemid 19139085)
39. van Kooten F., Ciabattoni G., Patrono C., Schmitz P. I., van Gijn J., Koudstaal P. J. Evidence for episodic platelet activation in acute ischemic stroke. Stroke: 1994; 25 2 278 281 (Pubitemid 24047245)
40. Feinberg W. M., Pearce L. A., Hart R. G., et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke: 1999; 30 12 2547 2553
41. Fisher M., Zipser R. Increased excretion of immunoreactive thromboxane B2 in cerebral ischemia. Stroke: 1985; 16 1 10 14 (Pubitemid 15194747)
42. van Kooten F., Ciabattoni G., Koudstaal P. J., Dippel D. W., Patrono C. Increased platelet activation in the chronic phase after cerebral ischemia and intracerebral hemorrhage. Stroke: 1999; 30 3 546 549 (Pubitemid 29115390)
43. Shah A. B., Beamer N., Coull B. M. Enhanced in vivo platelet activation in subtypes of ischemic stroke. Stroke: 1985; 16 4 643 647 (Pubitemid 15007238)
44. Iwamoto T., Kubo H., Takasaki M. Platelet activation in the cerebral circulation in different subtypes of ischemic stroke and Binswanger's disease. Stroke: 1995; 26 1 52 56
45. Del Zoppo G. J., Copeland B. R., Harker L. A., et al. Experimental acute thrombotic stroke in baboons. Stroke: 1986; 17 6 1254 1265 (Pubitemid 17008967)
46. Abumiya T., Fitridge R., Mazur C., et al. Integrin alpha(IIb)beta(3) inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. Stroke: 2000; 31 6 1402 1409, discussion 1409-1410
47. del Zoppo G. J., Schmid-Schönbein G. W., Mori E., Copeland B. R., Chang C. M. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke: 1991; 22 10 1276 1283
48. Garcia J. H., Liu K. F., Yoshida Y., Lian J., Chen S., del Zoppo G. J. Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat). Am J Pathol: 1994; 144 1 188 199 (Pubitemid 24158372)
49. Okada Y., Copeland B. R., Fitridge R., Koziol J. A., del Zoppo G. J. Fibrin contributes to microvascular obstructions and parenchymal changes during early focal cerebral ischemia and reperfusion. Stroke: 1994; 25 9 1847 1853, discussion 1853-1854
50. Choudhri T. F., Hoh B. L., Zerwes H. G., et al. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. J Clin Invest: 1998; 102 7 1301 1310 (Pubitemid 28467558)
51. Gent M., Blakely J. A., Easton J. D., et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet: 1989; 1 8649 1215 1220 (Pubitemid 19140324)
52. Britton M., Helmers C., Samuelsson K. A Swedish Cooperative Study. High-dose acetylsalicylic acid after cerebral infarction. Stroke: 1987; 18 325 334 (Pubitemid 17059656)
53. Gent M., Blakely J. A., Hachinski V., et al. A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke. Stroke: 1985; 16 3 416 424 (Pubitemid 15034421)
54. Scmidt E. V., Smirnov V. E., Ryabova V. S. Results of the seven-year prospective study of stroke patients. Stroke: 1988; 19 8 942 949
55. Wityk R. J., Pessin M. S., Kaplan R. F., Caplan L. R. Serial assessment of acute stroke using the NIH Stroke Scale. Stroke: 1994; 25 2 362 365 (Pubitemid 24047260)
56. Holroyd-Leduc J. M., Kapral M. K., Austin P. C., Tu J. V. Sex differences and similarities in the management and outcome of stroke patients. Stroke: 2000; 31 8 1833 1837 (Pubitemid 30620459)
57. Hurn P. D., Macrae I. M. Estrogen as a neuroprotectant in stroke. J Cereb Blood Flow Metab: 2000; 20 4 631 652 (Pubitemid 30217502)
58. McCullough L. D., Alkayed N. J., Traystman R. J., Williams M. J., Hurn P. D. Postischemic estrogen reduces hypoperfusion and secondary ischemia after experimental stroke. Stroke: 2001; 32 3 796 802
59. Silver F. L., Norris J. W., Lewis A. J., Hachinski V. C. Early mortality following stroke: a prospective review. Stroke: 1984; 15 3 492 496 (Pubitemid 14105963)
60. Shaw C-M, Alvord E. C. Jr, Berry R. G. Swelling of the brain following ischemic infarction with arterial occlusion. Arch Neurol: 1959; 1 161 177
61. Spetzler R. F., Selman W. R., Weinstein P., et al. Chronic reversible cerebral ischemia: evaluation of a new baboon model. Neurosurgery: 1980; 7 3 257 261 (Pubitemid 10002410)
62. Bogousslavsky J., Van Melle G., Regli F. The Lausanne Stroke Registry: analysis of 1,000 consecutive patients with first stroke. Stroke: 1988; 19 9 1083 1092
63. Foulkes M. A., Wolf P. A., Price T. R., Mohr J. P., Hier D. B. The Stroke Data Bank: design, methods, and baseline characteristics. Stroke: 1988; 19 5 547 554
64. International Stroke Trial Collaborative Group The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet: 1997; 349 9065 1569 1581
65. Chen Z. M., Sandercock P., Pan H. C., et al. Indications for early aspirin use in acute ischemic stroke: A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke: 2000; 31 6 1240 1249 (Pubitemid 30351240)
66. Hacke W., Kaste M., Fieschi C., et al. The European Cooperative Acute Stroke Study (ECASS) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA: 1995; 274 13 1017 1025
67. del Zoppo G. J. Acute stroke-on the threshold of a therapy? N Engl J Med: 1995; 333 24 1632 1633
68. Fisher C. M., Adams R. D. Observations on brain embolism with special reference to hemorrhage infarction. In: Furlan A. J., ed. The Heart and Stroke. Exploring Mutual Cerebrovascular and Cardiovascular Issues. 1st ed. New York Springer-Verlag: 1987; 17 36
69. Fisher M., Adams R. D. Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction. J Neuropathol Exp Neurol: 1951; 10 1 92 94
70. Jörgensen L., Torvik A. Ischaemic cerebrovascular diseases in an autopsy series. 2. Prevalence, location, pathogenesis, and clinical course of cerebral infarcts. J Neurol Sci: 1969; 9 2 285 320
71. Kwa V. I., Franke C. L., Verbeeten B. Jr, Stam J. Amsterdam Vascular Medicine Group Silent intracerebral microhemorrhages in patients with ischemic stroke. Ann Neurol: 1998; 44 3 372 377 (Pubitemid 28421442)
72. Okada Y., Yamaguchi T., Minematsu K., et al. Hemorrhagic transformation in cerebral embolism. Stroke: 1989; 20 5 598 603 (Pubitemid 19139086)
73. Hornig C. R., Dorndorf W., Agnoli A. L. Hemorrhagic cerebral infarction-a prospective study. Stroke: 1986; 17 2 179 185 (Pubitemid 16125236)
74. Yamaguchi T., Minematsu K., Choki J., Ikeda M. Clinical and neuroradiological analysis of thrombotic and embolic cerebral infarction. Jpn Circ J: 1984; 48 1 50 58 (Pubitemid 14174038)
75. Hamann G. F., Okada Y., Fitridge R., del Zoppo G. J. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke: 1995; 26 11 2120 2126
76. Hamann G. F., Okada Y., del Zoppo G. J. Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cereb Blood Flow Metab: 1996; 16 6 1373 1378 (Pubitemid 26365393)
77. Pessin M. S., Teal P. A., Caplan L. R. Hemorrhagic infarction: guilt by association? AJNR Am J Neuroradiol: 1991; 12 6 1123 1126
78. Cerebral Embolism Study Group Immediate anticoagulation of embolic stroke: brain hemorrhage and management options. Stroke: 1984; 15 5 779 789
79. Babikian V. L., Kase C. S., Pessin M. S., Norrving B., Gorelick P. B. Intracerebral hemorrhage in stroke patients anticoagulated with heparin. Stroke: 1989; 20 11 1500 1503 (Pubitemid 19278136)
80. Levine M. N., Raskob G., Landefeld S., Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest: 2001; 119 (1, Suppl): 108S 121S (Pubitemid 32154197)
81. Diener H. C., Cunha L., Forbes C., Sivenius J., Smets P., Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci: 1996; 143 1-2 1 13 (Pubitemid 26402780)
82. Baron J. C., von Kummer R., del Zoppo G. J. Treatment of acute ischemic stroke. Challenging the concept of a rigid and universal time window. (Editorial) Stroke: 1995; 26 12 2219 2221
83. von Kummer R., Meyding-Lamadé U., Forsting M., et al. Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk. AJNR Am J Neuroradiol: 1994; 15 1 9 15, discussion 16-18
84. Warach S., Gaa J., Siewert B., Wielopolski P., Edelman R. R. Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging. Ann Neurol: 1995; 37 2 231 241
85. Garcia J. H., Liu K. F., Ho K. L. Neuronal necrosis after middle cerebral artery occlusion in Wistar rats progresses at different time intervals in the caudoputamen and the cortex. Stroke: 1995; 26 4 636 642, discussion 643
86. Tagaya M., Liu K. F., Copeland B., et al. DNA scission after focal brain ischemia. Temporal differences in two species. Stroke: 1997; 28 6 1245 1254 (Pubitemid 27248903)
87. Astrup J., Siesjö B. K., Symon L. Thresholds in cerebral ischemia - the ischemic penumbra. Stroke: 1981; 12 6 723 725 (Pubitemid 12227362)
88. Branston N. M., Symon L., Crockard H. A., Pasztor E. Relationship between the cortical evoked potential and local cortical blood flow following acute middle cerebral artery occlusion in the baboon. Exp Neurol: 1974; 45 2 195 208
89. Astrup J., Symon L., Branston N. M., Lassen N. A. Cortical evoked potential and extracellular K+ and H+ at critical levels of brain ischemia. Stroke: 1977; 8 1 51 57
90. Branston N. M., Strong A. J., Symon L. Extracellular potassium activity, evoked potential and tissue blood flow. Relationships during progressive ischaemia in baboon cerebral cortex. J Neurol Sci: 1977; 32 3 305 321 (Pubitemid 8109810)
91. del Zoppo G. J., Sharp F. R., Heiss W-D, Albers G. W. Heterogeneity in the penumbra. J Cereb Blood Flow Metab: 2011; 31 9 1836 1851
92. Albers G. W., Thijs V. N., Wechsler L., et al. DEFUSE Investigators Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol: 2006; 60 5 508 517 (Pubitemid 44871793)
93. Olivot J. M., Mlynash M., Thijs V. N., et al. Relationships between cerebral perfusion and reversibility of acute diffusion lesions in DEFUSE: insights from RADAR. Stroke: 2009; 40 5 1692 1697
94. Heiss W. D. Ischemic penumbra: evidence from functional imaging in man. J Cereb Blood Flow Metab: 2000; 20 9 1276 1293
95. Zülch K-J. The Cerebral Infarct: Pathology, Pathogenesis, and Computed Tomography. 1st ed. Berlin Springer-Verlag: 1985
96. Bär T. Morphometric evaluation of capillaries in different laminae of rat cerebral cortex by automatic image analysis: Changes during development and aging. In: Cervos-Navarro J., ed.; Advances in Neurology. 20th ed. New York Raven Press: 1978; 1 9
97. Bär T. The vascular system of the cerebral cortex. Adv Anat Embryol Cell Biol: 1980; 59 I VI, 1-62
98. Russell R. WR. Observations on the retinal blood-vessels in monocular blindness. Lancet: 1961; 2 7218 1422 1428
99. Fields W. S., Lemak N. A., Frankowski R. F., Hardy R. J. Controlled trial of aspirin in cerebral ischemia. Stroke: 1977; 8 3 301 314 (Pubitemid 8103607)
100. The Canadian Cooperative Study Group A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med: 1978; 299 2 53 59
101. Bousser M. G., Eschwege E., Haguenau M., et al. "AICLAo" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke: 1983; 14 1 5 14 (Pubitemid 13174990)
102. The ESPS Group The European Stroke Prevention Study (ESPS). Principal end-points. Lancet: 1987; 2 8572 1351 1354
103. ESPS-2 Working Group Second European Stroke Prevention Study. ESPS-2 Working Group. J Neurol: 1992; 239 6 299 301
104. Halkes P. H., van Gijn J., Kappelle L. J., Koudstaal P. J., Algra A. ESPRIT Study Group Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet: 2006; 367 9523 1665 1673
105. Hass W. K., Easton J. D., Adams H. P. Jr., et al. Ticlopidine Aspirin Stroke Study Group A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med: 1989; 321 8 501 507 (Pubitemid 19203874)
106. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet: 1996; 348 9038 1329 1339
107. Diener H-C, Bogousslavsky J., Brass L. M., et al. MATCH investigators Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet: 2004; 364 9431 331 337
108. Bhatt D. L., Fox K. A., Hacke W., et al. CHARISMA Investigators Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med: 2006; 354 16 1706 1717
109. Campbell M. H. Basilar artery syndrome. Can Med Assoc J: 1953; 69 3 314 315
110. Millikan C. H., Siekert R. G., Shick R. M. Studies in cerebrovascular disease. III. The use of anticoagulant drugs in the treatment of insufficiency or thrombosis within the basilar arterial system. Proc Staff Meet Mayo Clin: 1955; 30 6 116 126
111. Baker R. N., Broward J. A., Fang H. C., et al. Anticoagulant therapy in cerebral infarction. Report on cooperative study. Neurology: 1962; 12 823 835
112. Baker R. N., Ramseyer J. C., Schwartz W. S. Prognosis in patients with transient cerebral ischemic attacks. Neurology: 1968; 18 1157 1165
113. Cerebral Embolism Study Group Immediate anticoagulation of embolic stroke: a randomized trial. Stroke: 1983; 14 5 668 676
114. Albers G. W. Antithrombotic agents in cerebral ischemia. Am J Cardiol: 1995; 75 6 34B 38B
115. Mohr J. P., Thompson J. LP, Lazar R. M., et al. Warfarin-Aspirin Recurrent Stroke Study Group A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med: 2001; 345 20 1444 1451
116. Fisher C. M. Anticoagulant therapy in cerebral thrombosis and cerebral embolism. A national cooperative study, interim report. Neurology: 1961; 11 4 119 131
117. Hill A. B., Marshall J., Shaw D. A. Cerebrovascular disease: trial of long-term anticoagulant therapy. BMJ: 1962; 2 5311 1003 1006
118. McDowell F., McDevitt E. Treatment of the completed stroke with long-term anticoagulant. Six and one-half years' experience. In: Siekert R. H., Whisnant J. R., eds. Cerebral Vascular Diseases, Fourth Princeton Conference. New York, NY Grune & Stratton: 1965; 185 199
119. Enger E., Boyesen S. Long-term anticoagulant therapy in patients with cerebral infarction: a controlled clinical study. Acta Med Scand: 1965; 179 (Suppl): 1 61
120. Baker R. N. An evaluation of anticoagulant therapy in the treatment of cerebrovascular disease. Report of the Veterans Administration Cooperative Study of Atherosclerosis, Neruology Section. Neurology: 1961; 11 4 132 138
121. CAST (Chinese Acute Stroke Trial) Collaborative Group CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet: 1997; 349 9066 1641 1649
122. Chen Z. M., Xie J. X., Peto R., et al. Chinese Acute Stroke Trial (CAST): rationale, design and progress. Cerebrovasc Dis: 1996; 6 23
123. Kay R., Wong K. S., Yu Y. L., et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med: 1995; 333 24 1588 1593
124. Berge E., Abdelnoor M., Nakstad P. H., Sandset P. M. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet: 2000; 355 9211 1205 1210 (Pubitemid 30184528)
125. Diener H. C., Ringelstein E. B., von Kummer R., et al. Therapy of Patients With Acute Stroke (TOPAS) Investigators Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Stroke: 2001; 32 1 22 29 (Pubitemid 32065699)
126. Bath P. M., Lindenstrom E., Boysen G., et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet: 2001; 358 9283 702 710 (Pubitemid 32823398)
127. Stutzmann J. M., Mary V., Wahl F., Grosjean-Piot O., Uzan A., Pratt J. Neuroprotective profile of enoxaparin, a low molecular weight heparin, in in vivo models of cerebral ischemia or traumatic brain injury in rats: a review. CNS Drug Rev: 2002; 8 1 1 30 (Pubitemid 34651313)
128. Liu M., Counsell C., Sandercock P. Anticoagulants for preventing recurrence following ischaemic stroke or transient ischaemic attack. Cochrane Database Syst Rev: 2000; 2 CD000248
129. Gubitz G., Counsell C., Sandercock P., Signorini D. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev: 2000; 2 CD000024
130. Petersen P., Boysen G., Godtfredsen J., Andersen E. D., Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet: 1989; 1 8631 175 179 (Pubitemid 19038801)
131. Stroke Prevention in Atrial Fibrillation Study Group Investigators Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med: 1990; 322 12 863 868
132. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med: 1990; 323 22 1505 1511
133. Stroke Prevention in Atrial Fibrillation Investigators Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet: 1996; 348 9028 633 638
134. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA: 1998; 279 1265 1272
135. EAFT (European Atrial Fibrillation Trial) Study Group Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet: 1993; 342 8882 1255 1262
136. The Atrial Fibrillation Investigators The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. Arch Intern Med: 1997; 157 11 1237 1240
137. Connolly S. J., Ezekowitz M. D., Yusuf S., et al. RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med: 2009; 361 12 1139 1151
138. Patel M. R., Mahaffey K. W., Garg J., et al. ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med: 2011; 365 10 883 891
139. del Zoppo G. J., Eliasziw M. New options in anticoagulation for atrial fibrillation. N Engl J Med: 2011; 365 10 952 953
140. Connolly S. J., Eikelboom J., Joyner C., et al. AVERROES Steering Committee and Investigators Apixaban in patients with atrial fibrillation. N Engl J Med: 2011; 364 9 806 817
141. Granger C. B., Alexander J. H., McMurray J. J., et al. ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med: 2011; 365 11 981 992
142. Coulshed N., Epstein E. J., McKendrick C. S., Galloway R. W., Walker E. Systemic embolism in mitral valve disease. Br Heart J: 1970; 32 1 26 34
143. Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. BMJ: 1964; 1 5392 1209 1212
144. Daley R., Mattingly T. W., Holt C. L., Bland E. F., White P. D. Systemic arterial embolism in rheumatic heart disease. Am Heart J: 1951; 42 4 566 581
145. Cannegieter S. C., Rosendaal F. R., Wintzen A. R., van der Meer F. J., Vandenbroucke J. P., Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med: 1995; 333 1 11 17
146. Stein P. D., Alpert J. S., Bussey H. I., Dalen J. E., Turpie A. G. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest: 2001; 119 (1, Suppl): 220S 227S (Pubitemid 32154202)
147. Horstkotte D., Schulte H., Bircks W., Strauer B. Unexpected findings concerning thromboembolic complications and anticoagulation after complete 10. year follow up of patients with St. Jude Medical prostheses. J Heart Valve Dis: 1993; 2 3 291 301
148. Horstkotte D., Scharf R. E., Schultheiss H. P. Intracardiac thrombosis: patient-related and device-related factors. J Heart Valve Dis: 1995; 4 2 114 120 (Pubitemid 26021267)
149. Levine H. J., Pauker S. G., Salzman E. W. Antithrombotic therapy in valvular heart disease. Chest: 1989; 95 (2, Suppl): 98S 106S (Pubitemid 19045159)
150. Stein P. D., Kantrowitz A. Antithrombotic therapy in mechanical and biological prosthetic heart valves and saphenous vein bypass grafts. Chest: 1989; 95 (2, Suppl): 107S 117S (Pubitemid 19045160)
151. Horstkotte D., Schulte H. D., Bircks W., Strauer B. E. Lower intensity anticoagulation therapy results in lower complication rates with the St. Jude Medical prosthesis. J Thorac Cardiovasc Surg: 1994; 107 4 1136 1145 (Pubitemid 24129907)
152. Stein P. D., Grandison D., Hua T. A., et al. Therapeutic level of oral anticoagulation with warfarin in patients with mechanical prosthetic heart valves: review of literature and recommendations based on international normalized ratio. Postgrad Med J: 1994; 70 01 S72 S83 (Pubitemid 24276913)
153. Dale J., Myhre E., Storstein O., Stormorken H., Efskind L. Prevention of arterial thromboembolism with acetylsalicylic acid. A controlled clinical study in patients with aortic ball valves. Am Heart J: 1977; 94 1 101 111 (Pubitemid 8245823)
154. Altman R., Boullon F., Rouvier J., Raca R., de la Fuente L., Favaloro R. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thorac Cardiovasc Surg: 1976; 72 1 127 129
155. Sullivan J. M., Harken D. E., Gorlin R. Effect of dipyridamole on the incidence of arterial emboli after cardiac valve replacement. Circulation: 1969; 39 5 01 I149 I153
156. Sullivan J. M., Harken D. E., Gorlin R. Pharmacologic control of thromboembolic complications of cardiac-valve replacement. N Engl J Med: 1971; 284 25 1391 1394
157. Altman R., Rouvier J., Gurfinkel E., Scazziota A., Turpie A. G. Comparison of high-dose with low-dose aspirin in patients with mechanical heart valve replacement treated with oral anticoagulant. Circulation: 1996; 94 9 2113 2116 (Pubitemid 26360502)
158. Kontozis L., Skudicky D., Hopley M. J., Sareli P. Long-term follow-up of St. Jude Medical prosthesis in a young rheumatic population using low-level warfarin anticoagulation: an analysis of the temporal distribution of causes of death. Am J Cardiol: 1998; 81 6 736 739 (Pubitemid 28146449)
159. Chesebro J. H., Fuster V., Elveback L. R., et al. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol: 1983; 51 9 1537 1541
160. Pouleur H., Buyse M. Effects of dipyridamole in combination with anticoagulant therapy on survival and thromboembolic events in patients with prosthetic heart valves. A meta-analysis of the randomized trials. J Thorac Cardiovasc Surg: 1995; 110 2 463 472
161. Massel D., Little S. H. Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis. Am Coll Cardiol: 2001; 37 569 578
162. Oyer P. E., Stinson E. B., Griepp R. B., Shumway N. E. Valve replacement with the Starr-Edwards and Hancock prostheses: comparative analysis of late morbidity and mortality. Ann Surg: 1977; 186 3 301 309 (Pubitemid 8170971)
163. Ionescu M. I., Smith D. R., Hasan S. S., Chidambaram M., Tandon A. P. Clinical durability of the pericardial xenograft valve: ten years experience with mitral replacement. Ann Thorac Surg: 1982; 34 3 265 277 (Pubitemid 12061868)
164. Williams J. B., Karp R. B., Kirklin J. W., et al. Considerations in selection and management of patients undergoing valve replacement with glutaraldehyde-fixed porcine bioprotheses. Ann Thorac Surg: 1980; 30 3 247 258 (Pubitemid 10048370)
165. Cohn L. H., Allred E. N., DiSesa V. J., Sawtelle K., Shemin R. J., Collins J. J. Jr. Early and late risk of aortic valve replacement. A 12. year concomitant comparison of the porcine bioprosthetic and tilting disc prosthetic aortic valves. J Thorac Cardiovasc Surg: 1984; 88 5 Pt 1 695 705
166. Kelton J. G. Antiplatelet agents: rationale and results. Clin Haematol: 1983; 12 1 311 354
167. Nuñez L., Aguado M. G., Celemín D., Iglesias A., Larrea J. L. Aspirin or Coumadin as the drug of choice for valve replacement with porcine bioprosthesis. Ann Thorac Surg: 1982; 33 4 354 358 (Pubitemid 12147856)
168. Nuñez L., Gil Aguado M., Larrea J. L., Celemín D., Oliver J. Prevention of thromboembolism using aspirin after mitral valve replacement with porcine bioprosthesis. Ann Thorac Surg: 1984; 37 1 84 87
169. Breddin K., Loew D., Lechner K., Uberla K., Walter E. Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Haemostasis: 1980; 9 6 325 344 (Pubitemid 10056753)
170. Hurlen M., Smith P., Arnesen H. Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. The WARIS-II (Warfarin-Aspirin Reinfarction Study) design. Scand Cardiovasc J: 2000; 34 2 168 171
171. Hurlen M., Abdelnoor M., Smith P., Erikssen J., Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med: 2002; 347 13 969 974
172. Hurlen M., Eikvar L., Seljeflot I., Arnesen H. Occult bleeding in three different antithrombotic regimes after myocardial infarction. A WARIS-II
173. Meyer J. S., Herndon R. M., Gotoh F., Tazaki Y., Nelson J. N., Johnson J. F. Therapeutic thrombolysis. In: Millikan C. H., Siekert R. G., Whisnant J. P., eds. Cerebral Vascular Diseases, Third Princeton Conference. New York Grune and Stratton: 1961; 160 177
174. Sherry S. Historical developments in fibrinolysis. In: Sawaya R., ed. Fibrinolysis and the Central Nervous System. Philadelphia Hanley & Belfus, Inc.: 1990; 3 13
175. Abe T., Kazawa M., Naito I., et al. Clinical effect of urokinase (60,000 units/day) on cerebral infarction-Comparative study by means of multiple center double-blind test. Blood Vessels: 1981; 12 342 358
176. Abe T., Kazama M., Naito I., et al. Clinical evaluation for efficacy of tissue culture urokinase (TCUK) on cerebral thrombosis by means of multicenter double-blind study. Blood Vessels: 1981; 12 321 341
177. Fletcher A. P., Alkjaersig N., Lewis M., et al. A pilot study of urokinase therapy in cerebral infarction. Stroke: 1976; 7 2 135 142
178. Del Zoppo G. J., Zeumer H., Harker L. A. Thrombolytic therapy in stroke: possibilities and hazards. Stroke: 1986; 17 4 595 607 (Pubitemid 16066523)
179. Atarashi J., Otomo E., Araki G., et al. Clinical utility of urokinase in the treatment of acute stage of cerebral thrombosis: multi-center double-blind study in comparison with placebo. Clin Eval: 1985; 13 659 709
180. Otomo E., Araki G., Itoh E., et al. Clinical efficacy of urokinase in the treatment of cerebral thrombosis. Clin Eval: 1985; 13 711 751
181. Abe T., Terashi A., Tohgi H., Sasoh S., Naito I. Clinical efficacy of intravenous administration of SM-9527 (t-PA) in cerebral thrombosis. Clin Eval: 1990; 18 39 69
182. Otomo E., Tohgi H., Hirai S., et al. Clinical efficacy of AK-124 (tissue plasminogen activator) in the treatment of cerebral thrombosis: study by means of multicenter double-blind comparison with urokinase. Yakuri To Chiryo: 1988; 16 3775 3821
183. Baron J. C. Perfusion thresholds in human cerebral ischemia: historical perspective and therapeutic implications. Cerebrovasc Dis: 2001; 11 01 2 8
184. Mori E., Tabuchi M., Yoshida T., Yamadori A. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke: 1988; 19 7 802 812
185. del Zoppo G. J., Ferbert A., Otis S., et al. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke. A pilot study. Stroke: 1988; 19 3 307 313
186. Matsumoto K., Satoh K. Topical intraarterial urokinase infusion for acute stroke. In: Hacke W., del Zoppo G. J., Hirschberg M., eds. Thrombolytic Therapy in Acute Ischemic Stroke. Heidelberg, Germany Springer-Verlag: 1991; 207 212
187. Mori E., Yoneda Y., Tabuchi M., et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology: 1992; 42 5 976 982
188. Yamaguchi T. Intravenous rt-PA in acute embolic stroke. In: Hacke W., del Zoppo G. J., Hirschberg M., eds. Thrombolytic Therapy in Acute Ischemic Stroke. Heidelberg, Germany Springer-Verlag: 1991; 168 174
189. von Kummer R., Forsting M., Sartor K., Hacke W. Intravenous recombinant tissue plasminogen activator in acute stroke. In: Hacke W., del Zoppo G. J., Hirschberg M., eds. Thrombolytic Therapy in Acute Ischemic Stroke. Heidelberg, Germany Springer-Verlag: 1991; 161 167
190. del Zoppo G. J. Thrombolysis: New concepts in the treatment of stroke. In: Hennerici M., Sitzer G., Weger H-D., eds. Carotid Artery Plaques. Karger Basel: 1988; 247 272
191. Hommel M., Boissel J. P., Cornu C., et al. Termination of trial of streptokinase in severe acute ischemic stroke. Lancet: 1995; 345 578 579
192. Donnan G. A., Davis S. M., Chambers B. R., et al. Trials of streptokinase in severe acute ischaemic stroke. Lancet: 1995; 345 8949 578 579
193. Multicenter Acute Stroke Trial-Italy (MAST-I) Group Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Lancet: 1995; 346 8989 1509 1514
194. Kwiatkowski T. G., Libman R. B., Frankel M., et al. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med: 1999; 340 23 1781 1787 (Pubitemid 29266401)
195. Albers G. W., Bates V. E., Clark W. M., Bell R., Verro P., Hamilton S. A. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA: 2000; 283 9 1145 1150 (Pubitemid 30126602)
196. Hacke W., Kaste M., Fieschi C., et al. Second European-Australasian Acute Stroke Study Investigators Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet: 1998; 352 9136 1245 1251 (Pubitemid 28470336)
197. von Kummer R., Allen K. L., Holle R., et al. Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology: 1997; 205 2 327 333 (Pubitemid 27467308)
198. Wahlgren N., Ahmed N., Dávalos A., et al. SITS-MOST investigators Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet: 2007; 369 9558 275 282 (Pubitemid 46138121)
199. Wahlgren N., Ahmed N., Dávalos A., et al. SITS investigators Thrombolysis with alteplase 3-4.5. h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet: 2008; 372 9646 1303 1309
200. Hacke W., Kaste M., Bluhmki E., et al. ECASS Investigators Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med: 2008; 359 13 1317 1329
201. Hacke W., Kaste M., Fieschi C., et al. Second European-Australasian Acute Stroke Study Investigators Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet: 1998; 352 9136 1245 1251 (Pubitemid 28470336)
202. Clark W. M., Albers G. W., Madden K. P., Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke: 2000; 31 4 811 816 (Pubitemid 30198420)
203. Clark W. M., Wissman S., Albers G. W., Jhamandas J. H., Madden K. P., Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA: 1999; 282 21 2019 2026
204. Del Zoppo G. J., Saver J. L., Jauch E. C., Adams H. P. Jr. American Heart Association Stroke Council Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke: 2009; 40 8 2945 2948
205. Yamaguchi T., Hayakawa T., Kikuchi H. for the Japanese Thrombolysis Study Group Intravenous tissue plasminogen activator in acute thromboembolic stroke: A placebo-controlled, double-blind trial. In: del Zoppo G. J., Mori E., Hacke W., eds. Thrombolytic Therapy in Acute Ischemic Stroke II. Heidelberg, Germany Springer-Verlag: 1993; 59 65
206. Hacke W., Donnan G., Fieschi C., et al. ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet: 2004; 363 9411 768 774
207. Levy D. E., Brott T. G., Haley E. C. Jr., et al. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke: 1994; 25 2 291 297 (Pubitemid 24047248)
208. Larrue V., von Kummer R., del Zoppo G. J., Bluhmki E. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke: 1997; 28 5 957 960 (Pubitemid 27209140)
209. Larrue V., von Kummer R R., Müller A., Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke: 2001; 32 2 438 441 (Pubitemid 32155231)
210. Dubey N., Bakshi R., Wasay M., Dmochowski J. Early computed tomography hypodensity predicts hemorrhage after intravenous tissue plasminogen activator in acute ischemic stroke. J Neuroimaging: 2001; 11 2 184 188 (Pubitemid 34163348)
211. Kalafut M. A., Schriger D. L., Saver J. L., Starkman S. Detection of early CT signs of >1/3 middle cerebral artery infarctions: interrater reliability and sensitivity of CT interpretation by physicians involved in acute stroke care. Stroke: 2000; 31 7 1667 1671 (Pubitemid 30437521)
212. Wardlaw J. M., Murray V., Berge E., Del Zoppo G. J. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev: 2009; 4 CD000213
213. Haley E. C. Jr, Lyden P. D., Johnston K. C., Hemmen T. M. TNK in Stroke Investigators A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke: 2005; 36 3 607 612 (Pubitemid 40344164)
214. Parsons M., Spratt N., Bivard A., et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med: 2012; 366 12 1099 1107
215. Hacke W., Albers G., Al-Rawi Y., et al. DIAS Study Group The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke: 2005; 36 1 66 73 (Pubitemid 40054177)
216. Furlan A. J., Eyding D., Albers G. W., et al. DEDAS Investigators Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke: 2006; 37 5 1227 1231 (Pubitemid 43731867)
217. Hacke W., Furlan A. J., Al-Rawi Y., et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol: 2009; 8 2 141 150
218. Caplan L. R. "Top of the basilaro" syndrome. Neurology: 1980; 30 1 72 79
219. Archer C. R., Horenstein S. Basilar artery occlusion: clinical and radiological correlation. Stroke: 1977; 8 3 383 390 (Pubitemid 8103622)
220. Nenci G. G., Gresele P., Taramelli M., Agnelli G., Signorini E. Thrombolytic therapy for thromboembolism of vertebrobasilar artery. Angiology: 1983; 34 9 561 571 (Pubitemid 13001269)
221. Hacke W., Zeumer H., Ferbert A., Brückmann H., del Zoppo G. J. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke: 1988; 19 10 1216 1222
222. Zeumer H., Freitag H. J., Grzyska U., Neunzig H. P. Local intraarterial fibrinolysis in acute vertebrobasilar occlusion. Technical developments and recent results. Neuroradiology: 1989; 31 4 336 340 (Pubitemid 19239754)
223. Mobius E., Berg-Dammer E., Kuhne D., Aster H. C. Local thrombolytic therapy in acute basilar artery occlusion. In: Hacke W., del Zoppo G. J., Hirschberg M., eds.; Thrombolytic Therapy in Acute Ischemic Stroke. Berlin, Germany Springer Verlag: 1991; 213 215
224. Furlan A. J., Higashida R., Wechsler L., et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA: 1999; 282 21 2003 2011
225. Bell W. R. Jr, Bells W. R. Jr. Defibrinogenating enzymes. Drugs: 1997; 54 03 18 30, discussion 30-31
226. The Ancrod Stroke Study Investigators Ancrod for the treatment of acute ischemic brain infarction. Stroke: 1994; 25 9 1755 1759
227. Krishnamurti C., Barr C. F., Hassett M. A., Young G. D., Alving B. M. Plasminogen activator inhibitor: a regulator of ancrod-induced fibrin deposition in rabbits. Blood: 1987; 69 3 798 803 (Pubitemid 17057459)
228. Sherman D. G., Atkinson R. P., Chippendale T., et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA: 2000; 283 18 2395 2403 (Pubitemid 30257538)
229. Orgogozo J. M., Verstraete M., Kay R., Hennerici M., Lenzi G. L. Outcomes of ancrod in acute ischemic stroke. Independent Data and Safety Monitoring Board for ESTAT. Steering Committee for ESTAT. European Stroke Treatment with Ancrod Trial. JAMA: 2000; 284 15 1926 1927
230. Levy D. E., del Zoppo G. J., Demaerschalk B. M., et al. Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program. Stroke: 2009; 40 12 3796 3803
231. Borhani Haghighi A., Edgell R. C., Cruz-Flores S., et al. Mortality of cerebral venous-sinus thrombosis in a large national sample. Stroke: 2012; 43 1 262 264
232. Guo X. B., Guan S., Fan Y., Song L. J. Local thrombolysis for severe cerebral venous sinus thrombosis. AJNR Am J Neuroradiol: 2012; 33 6 1187 1190
233. Sidani C. A., Ballourah W., El Dassouki M., et al. Venous sinus thrombosis leading to stroke in a patient with sickle cell disease on hydroxyurea and high hemoglobin levels: treatment with thrombolysis. Am J Hematol: 2008; 83 10 818 820
234. Weatherby S. JM, Edwards N. C., West R., Heafield M. TE. Good outcome in early pregnancy following direct thrombolysis for cerebral venous sinus thrombosis. J Neurol: 2003; 250 11 1372 1373 (Pubitemid 37456900)
235. Yamini B., Loch Macdonald R., Rosenblum J. Treatment of deep cerebral venous thrombosis by local infusion of tissue plasminogen activator. Surg Neurol: 2001; 55 6 340 346
236. Wasay M., Bakshi R., Kojan S., Bobustuc G., Dubey N., Unwin D. H. Nonrandomized comparison of local urokinase thrombolysis versus systemic heparin anticoagulation for superior sagittal sinus thrombosis. Stroke: 2001; 32 10 2310 2317
237. Wasay M., Dai A. I., Ansari M., Shaikh Z., Roach E. S. Cerebral venous sinus thrombosis in children: a multicenter cohort from the United States. J Child Neurol: 2008; 23 1 26 31
238. Anderson D. C., Kappelle L. J., Eliasziw M., Babikian V. L., Pearce L. A., Barnett H. J. Occurrence of hemispheric and retinal ischemia in atrial fibrillation compared with carotid stenosis. Stroke: 2002; 33 8 1963 1967 (Pubitemid 34840050)
239. Bashshur Z. F., Taher A., Masri A. F., Najjar D., Arayssi T. K., Noureddin B. N. Anticardiolipin antibodies in patients with retinal vein occlusion and no risk factors: a prospective study. Retina: 2003; 23 4 486 490 (Pubitemid 37071961)
240. Kwaan H. C. Thromboembolic disorders of the eye. In: Comerota A. C., ed. Thrombolytic Therapy. Orlando, FL Grune & Stratton: 1988; 153 163
241. Hattenbach L. O., Wellermann G., Steinkamp G. W., Scharrer I., Koch F. H., Ohrloff C. Visual outcome after treatment with low-dose recombinant tissue plasminogen activator or hemodilution in ischemic central retinal vein occlusion. Ophthalmologica: 1999; 213 6 360 366 (Pubitemid 29524922)
242. Freitag H-J, Zeumer H., Knospe V. Acute central retinal artery occlusion and the role of thrombolysis. In: del Zoppo G. J., Mori E., Hacke W., eds. Thrombolytic Therapy in Acute Ischemic Stroke II. Heidelberg, Germany Springer-Verlag: 1993; 103 105
243. Schmidt D., Schumacher M., Wakhloo A. K. Microcatheter urokinase infusion in central retinal artery occlusion. Am J Ophthalmol: 1992; 113 4 429 434
244. Hattenbach L. O., Friedrich Arndt C., Lerche R., et al. Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion. Retina: 2009; 29 7 932 940
245. Costen M. T., Donaldson W. B., Olson J. A. Acute central retinal vein occlusion successfully treated with intravenous thrombolysis. Br J Ophthalmol: 1999; 83 10 1196 1197 (Pubitemid 29469132)
246. Chen C. S., Lee A. W., Campbell B., et al. Study of the efficacy of intravenous tissue plasminogen activator in central retinal artery occlusion. Int J Stroke: 2011; 6 1 87 89
247. Hattenbach L. O., Puchta J., Hilgenberg I. Experimental endoscopic endovascular cannulation: a novel approach to thrombolysis in retinal vessel occlusion. Invest Ophthalmol Vis Sci: 2012; 53 1 42 46
248. Schwenn O. K., Wüstenberg E. G., Konerding M. A., Hattenbach L. O. Experimental percutaneous cannulation of the supraorbital arteries: implication for future therapy. Invest Ophthalmol Vis Sci: 2005; 46 5 1557 1560 (Pubitemid 44843585)
249. The TIMI Study Group Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med: 1989; 320 10 618 627
250. Rao A. K., Pratt C., Berke A., et al. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol: 1988; 11 1 1 11 (Pubitemid 18029027)
251. Mori E. Safety and efficacy of 0.6 mg/kg rt-PA: optimum rt-PA dose revisited. Ann N Y Acad Sci: 2012; 1268 108 112
252. Yamaguchi T., Mori E., Minematsu K., et al. Japan Alteplase Clinical Trial (J-ACT) Group Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke: 2006; 37 7 1810 1815 (Pubitemid 44297734)
253. Nakagawara J., Minematsu K., Okada Y., et al. J-MARS Investigators Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke: 2010; 41 9 1984 1989
254. Slivka A., Pulsinelli W. A. Hemorrhagic complications of thrombolytic therapy in experimental stroke. Stroke: 1987; 18 1148 1156 (Pubitemid 18014487)
255. Edvinsson L., MacKenzie E. T., McCulloch J. General and comparative anatomy of the cerebral circulation. In: Edvinsson L., MacKenzie E. T., McCulloch J., eds. Cerebral Blood Flow and Metabolism. 1 ed. New York Raven Press: 1993; 3 39
256. Lansberg M. G., Straka M., Kemp S., et al. DEFUSE 2 study investigators MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. Lancet Neurol: 2012; 11 10 860 867
257. The Abciximab in Ischemic Stroke Investigators Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke: 2000; 31 3 601 609
258. Pancioli A. M., Broderick J., Brott T., et al. CLEAR Trial Investigators The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke: 2008; 39 12 3268 3276
259. Ezekowitz M. D., Reilly P. A., Nehmiz G., et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol: 2007; 100 9 1419 1426 (Pubitemid 47576022)
260. IMS Study Investigators Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke: 2004; 35 4 904 911
261. IMS II Trial Investigators The Interventional Management of Stroke (IMS) II Study. Stroke: 2007; 38 7 2127 2135
262. Qureshi A. I., Hussein H. M., Abdelmoula M., Georgiadis A. L., Janjua N. Subacute recanalization and reocclusion in patients with acute ischemic stroke following endovascular treatment. Neurocrit Care: 2009; 10 2 195 203
263. Janjua N., Alkawi A., Suri M. F., Qureshi A. I. Impact of arterial reocclusion and distal fragmentation during thrombolysis among patients with acute ischemic stroke. AJNR Am J Neuroradiol: 2008; 29 2 253 258 (Pubitemid 351287876)
264. Alexandrov A. V., Grotta J. C. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology: 2002; 59 6 862 867
265. Zinkstok S. M., Roos Y. B. ARTIS investigators Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet: 2012; 380 9843 731 737
266. De Haan R., Horn J., Limburg M., Van Der Meulen J., Bossuyt P. A comparison of five stroke scales with measures of disability, handicap, and quality of life. Stroke: 1993; 24 8 1178 1181 (Pubitemid 23237556)
267. del Zoppo GJ, Koziol JA. Recanalization and stroke outcome. Circulation 2007;115(20):2602-2605